BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etentamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etentamig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06223516-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Etentamig: Phase 1 readout est. (NCT06223516)
DESCRIPTION:Etentamig\, phase 1\, Multiple Myeloma.\nStudy: Study of ABBV-3
 83 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) I
 njection in Adult Participants With Relapsed or Refractory Multiple Myelom
 a\nEstimated primary completion: February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06223516
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Etentamig: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: Study Assessing
  Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Availa
 ble Therapies in Adult Participants With Relapsed or Refractory Multiple M
 yeloma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158854-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06158854)
DESCRIPTION:Etentamig\, phase 1/2\, AL Amyloidosis.\nStudy: A Study to Asse
 ss Change in Disease Activity and Adverse Events (AE)s in Adult Participan
 ts With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (A
 BBV-383) as an Intravenous (IV) Infusion\nEstimated primary completion: Fe
 bruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 158854
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05650632-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Etentamig: Phase 1 readout est. (NCT05650632)
DESCRIPTION:Etentamig\, phase 1\, Multiple Myeloma.\nStudy: A Study to Asse
 ss Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Ad
 ult Participants With Relapsed or Refractory Multiple Myeloma\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/etentamig#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05650632
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alo
 ne or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in A
 dult Participants With Multiple Myeloma (MM)\nEstimated primary completion
 : December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eten
 tamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06953960
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728188-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Etentamig: Phase 3 readout est. (NCT07728188)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eval
 uate Adverse Events and Change in Disease Activity With Injected Etentamig
  Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed 
 or Refractory Multiple Myeloma\nEstimated primary completion: February 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07728188
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259839-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Etentamig: Phase 1 readout est. (NCT05259839)
DESCRIPTION:Etentamig\, phase 1\, Multiple Myeloma.\nStudy: A Study to Asse
 ss Adverse Events and Change in Disease Activity of Intravenously (IV) Inf
 used Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the
  Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
 \nEstimated primary completion: September 2033. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05259839
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793422-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Etentamig: Phase 3 readout est. (NCT07793422)
DESCRIPTION:Etentamig\, phase 3\, AL Amyloidosis.\nStudy: Study to Evaluate
  Change in Disease Activity and Adverse Events of Subcutaneous Etentamig C
 ompared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexame
 thasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis\
 nEstimated primary completion: December 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07793422
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Change in Disease Activity and Adverse Events (AE)s in Adult Particip
 ants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antib
 odies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nEst
 imated primary completion: December 2035. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06896916-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20360331
DTEND;VALUE=DATE:20360401
SUMMARY:Etentamig: Phase 1 readout est. (NCT06896916)
DESCRIPTION:Etentamig\, phase 1\, Multiple Myeloma.\nStudy: Study of Intrav
 enously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Lig
 ase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in 
 Disease Activity in Adult Participants With Relapsed or Refractory Multipl
 e Myeloma\nEstimated primary completion: March 2036. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06896916
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600151-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT07600151)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: Etenta-Isa-VR
 d in Newly Diagnosed High-Risk Multiple Myeloma\nEstimated primary complet
 ion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/etentamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07600151
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420959-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20360930
DTEND;VALUE=DATE:20361001
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT07420959)
DESCRIPTION:Etentamig\, phase 1/2.\nStudy: ABBV-383 for the Treatment of Re
 lapsed Refractory Waldenström Macroglobulinemia\nEstimated primary comple
 tion: 30 September 2036. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/etentamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07420959
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095452-3229@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20410331
DTEND;VALUE=DATE:20410401
SUMMARY:Etentamig: Phase 2/3 readout est. (NCT07095452)
DESCRIPTION:Etentamig\, phase 2/3\, Multiple Myeloma.\nStudy: A Study to As
 sess A Change in Disease Activity and Adverse Events of Intravenous Etenta
 mig and Daratumumab (Etentamig+D) Compared to Daratumumab\, Lenalidomide\,
  and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multip
 le Myeloma Not Eligible for Transplant\nEstimated primary completion: Marc
 h 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0709545
 2
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
